T-cells

By Targets:	Nuclear Factor of activated T Cells (NFAT) (10) ADC Cytotoxin (1) Adenosine Receptor (2) Akt (1) AMPK (1) Amyloid-β (1) Androgen Receptor (1) Antibiotic (5) Antifolate (1) Apoptosis (35) Arenavirus (1) Aryl Hydrocarbon Receptor (5) Autophagy (9) Bacterial (7) Biochemical Assay Reagents (4) Btk (2) c-Fms (1) c-Met/HGFR (1) c-Myc (1) Calcium Channel (3) Carbonic Anhydrase (1) Casein Kinase (4) Caspase (2) Cathepsin (2) CCR (3) CD19 (5) CD2 (2) CD20 (5) CD28 (6) CD3 (19) CD6 (1) CD73 (1) CDK (2) CFTR (1) COX (3) CRAC Channel (3) CRM1 (1) CTLA-4 (6) CXCR (5) Cytochrome P450 (2) DGK (9) Dipeptidyl Peptidase (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (2) DOCK (1) Drug Metabolite (4) DYRK (1) E1/E2/E3 Enzyme (4) EBI2/GPR183 (1) EGFR (2) Endogenous Metabolite (8) ERK (1) Eukaryotic Initiation Factor (eIF) (1) Fungal (3) GABA Receptor (2) Galectin (1) GHSR (1) Glutaminase (1) GSK-3 (1) HDAC (4) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (5) Histone Methyltransferase (2) HIV (9) HSP (2) IFNAR (5) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (4) Integrin (3) Interleukin Related (13) Isocitrate Dehydrogenase (IDH) (1) Isotope-Labeled Compounds (3) Itk (5) JAK (3) Keap1-Nrf2 (1) LAG-3 (6) Ligands for E3 Ligase (5) Ligands for Target Protein for PROTAC (1) Liposome (4) LPL Receptor (2) MAGL (1) MALT1 (1) MAP4K (6) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (1) Molecular Glues (4) Monoamine Oxidase (2) mTOR (1) Mucin (1) Necroptosis (2) NF-κB (10) NO Synthase (4) Notch (2) Nuclear Hormone Receptor 4A/NR4A (1) Nucleoside Antimetabolite/Analog (4) Orexin Receptor (OX Receptor) (1) P-glycoprotein (1) p38 MAPK (2) PD-1/PD-L1 (41) PDI (1) Phosphatase (12) Phospholipase (1) PI3K (5) PKA (1) PKC (6) Potassium Channel (6) PPAR (1) PROTACs (3) Pyroptosis (1) RAR/RXR (2) Reactive Oxygen Species (2) RIP kinase (1) ROR (5) SARS-CoV (3) Ser/Thr Protease (1) SHP2 (4) Sirtuin (1) Src (3) STAT (5) STING (1) Survivin (2) Tim3 (2) TNF Receptor (13) Toll-like Receptor (TLR) (4) Topoisomerase (3) TRP Channel (3) Wnt (2) β-catenin (4) γ-secretase (1)
By Research Areas:	Cancer (232) Cardiovascular Disease (6) Endocrinology (3) Infection (27) Inflammation/Immunology (231) Metabolic Disease (23) Neurological Disease (19)
Click Chemistry:	Azide (1) Alkynes (1)

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136427

KRM-III	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC₅₀ of ~5 μM. Anti-inflammatory activity .

HY-108813

Belatacept BMS 224818; LEA 29Y	Others	Inflammation/Immunology
Belatacept (BMS 224818) is a selective T-cell costimulation blocker. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants .

HY-124416

ML604086	CCR	Inflammation/Immunology Endocrinology
ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca ²⁺ concentrations .

HY-P2455

LLO (91-99) Listeriolysin O (91-99)	Bacterial	Inflammation/Immunology
LLO (91-99) (Listeriolysin O (91-99)), an exotoxin, is a class I MHC-restricted T-cell epitopes of listeriolysin (LLO). LLO (91-99) is an essential antigen for induction of T-cell mediated immunity in vivo .

HY-110113

CTA056	Btk	Cancer
CTA056 is an ITK (IL-2-inducible T-cell kinase) inhibitor with an IC₅₀ of 0.1 μM. CTA056 selectively targets malignant T cells and modulates oncomirs. CTA056 induces apoptosis and is a potential therapeutic agent for the research of T-cell leukemia and lymphoma .

HY-149773S

HPK1-IN-40-d2	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC₅₀ of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity .

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-N4053

Heraclenin	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Heraclenin, a natural furanocoumarin, significantly inhibits T cell receptor-mediated proliferation in human primary T cells in a concentration-dependent manner by targeting nuclear factor of activated T-cells (NFAT) .

HY-P99378

Neihulizumab ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)	Apoptosis	Inflammation/Immunology
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-153888

M351-110

Others Others

M351-110 is a T-cell activating V-domain immunoglobulin inhibitory factor agonist for cancer research .

M351-110	Others	Others
M351-110 is a T-cell activating V-domain immunoglobulin inhibitory factor agonist for cancer research .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells* to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-147311

NSC622608

PD-1/PD-L1 Inflammation/Immunology

NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC₅₀ value of 4.8 μM .

NSC622608	PD-1/PD-L1	Inflammation/Immunology
NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC₅₀ value of 4.8 μM .

HY-108601A

(S)-Ro 32-0432	PKC	Neurological Disease Inflammation/Immunology
(S)-Ro 32-0432 is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC₅₀ values of (S)-Ro 32-0432 for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research .

HY-P99679

Izuralimab

PD-1/PD-L1 Inflammation/Immunology Cancer

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 .
HY-N1726

cis-Burchellin

cis-Burchellin is a bioactive neolignan with anti-allergic activity. cis-Burchellin inhibits IL-2 production in Jurkat T-cells .

Izuralimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 .

cis-Burchellin
cis-Burchellin is a bioactive neolignan with anti-allergic activity. cis-Burchellin inhibits IL-2 production in Jurkat T-cells .

HY-106934

Peldesine BCX 34	Nucleoside Antimetabolite/Analog HIV	Infection Inflammation/Immunology Cancer
Peldesine (BCX 34) is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC₅₀s of 36 nM, 5 nM, and 32 nM for *human, rat, and mouse red blood cell* (RBC) PNP, respectively. Peldesine is also a T-cell proliferation inhibitor with an IC₅₀** of 800 nM. Peldesine has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research .

HY-106934A

Peldesine dihydrochloride BCX 34 dihydrochloride	Nucleoside Antimetabolite/Analog HIV	Infection Inflammation/Immunology Cancer
Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC₅₀s of 36 nM, 5 nM, and 32 nM for *human, rat, and mouse red blood cell* (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC₅₀** of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research .

HY-108601

(S)-Ro 32-0432 free base	PKC	Inflammation/Immunology
(S)-Ro 32-0432 free base is a potent, selective, ATP-competitive and orally active PKC inhibitor. The IC₅₀ values of (S)-Ro 32-0432 free base for PKCα, PKCβI, PKCβII, PKCγ and PKCε are 9.3 nM, 28 nM, 30 nM, 36.5 nM and 108.3 nM, respectively. (S)-Ro 32-0432 free base is also a selective G protein-coupled receptor kinase 5 (GRK5) inhibitor. (S)-Ro 32-0432 free base prevents T-cell activation and has the potential for chronic inflammatory and autoimmune diseases research .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-100365

Remetinostat SHP-141
Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of histone deacetylase enzymes (HDAC) which is under development for the treatment of cutaneous T-cell lymphoma .

HY-P1736

Influenza HA (126-138)	Influenza Virus	Infection
Influenza HA (126-138) is a influenza virus hemagglutinin (HA) peptide comprising amino acids 126-138, induces thymic and peripheral T-cell apoptosis .

HY-114388

QM385 2 Publications Verification	Others	Inflammation/Immunology
QM385 is a potent sepiapterin reductase (SPR) inhibitor with an IC₅₀ of 1.49 nM, which blocks T-cell proliferation and autoimmunity at nanomolar potency and with good oral bioavailability .

HY-P3747

Hemagglutinin (48-68)	Influenza Virus	Infection
Hemagglutinin (48-68) is the 48-68 fragment of influenza virus hemagglutinin. Hemagglutinin (48-68) can induce proliferation of the peptide specific T-cell clones .

HY-156769

Cbl-b-IN-13

E1/E2/E3 Enzyme Inflammation/Immunology

Cbl-b-IN-13 (Example 520) is a Cbl-b inhibitor with an IC₅₀ of <100 nM. Cbl-b-IN-13 has the ability to activate T-cells .

Cbl-b-IN-13	E1/E2/E3 Enzyme	Inflammation/Immunology
Cbl-b-IN-13 (Example 520) is a Cbl-b inhibitor with an IC₅₀ of <100 nM. Cbl-b-IN-13 has the ability to activate T-cells .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-101112

Okicenone
Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation .

HY-128726

ITK inhibitor 2	Itk	Inflammation/Immunology
ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC₅₀ of 2 nM.

HY-157149

DS21150768

MAP4K Cancer

DS21150768 is a potent, orally active HPK1 inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects .

DS21150768	MAP4K	Cancer
DS21150768 is a potent, orally active HPK1 inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects .

HY-134950

(E)-C-HDMAPP ammonium	TNF Receptor	Inflammation/Immunology
(E)-C-HDMAPP ammonium, is a potent phosphoantigen in ammonium form as well as a pyrophosphonate form of (E)-HDMAPP. (E)-C-HDMAPP is also an effective activator of γδ-T cells, induces T-cell stimulatory responses in vitro (EC₅₀=0.91 nM for TNF-α release) .

HY-P99024

Glofitamab RO7082859	CD20	Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma .

HY-P99040

Onvatilimab JNJ-61610588	PD-1/PD-L1	Cancer
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-*VISTA (V-domain Ig Suppressor of T-cell* Activation)** monoclonal antibody. Onvatilimab has an anti-tumor activity .

HY-155847

LYP-IN-3	Phosphatase	Cancer
LYP-IN-3 (compound D34) is a selective inhibitor of Lymphoid-tyrosine phosphatase (LYP) (Ki=0.93 μM), and regulates T-cell receptor (TCR) signaling pathway in tumor progress. LYP-IN-3 activates T-cell and inhibits M2 macrophage polarization, but upregulates PD-1/PD-L1 expression. LYP-IN-3 can be leveraged with PD-1/PD-L1 inhibitor, for futher cancer immunotherapy .

HY-141864

ITK/TRKA-IN-1	Itk	Inflammation/Immunology
ITK/TRKA-IN-1 is a dual inhibitor of *IL-2-inducible T-cell* kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC₅₀** value of 1.0 nM and 96 % inhibition, respectively.

HY-P99717

Lulizumab pegol BMS-931699	CD28	Inflammation/Immunology
Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease .

HY-109108

Valemetostat 1 Publications Verification DS-3201	Histone Methyltransferase	Cancer
Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma .

HY-111149

PS372424	CXCR	Inflammation/Immunology
PS372424, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 prevents human T-cell migration in a humanized model of arthritic inflammation .

HY-109108A

Valemetostat tosylate 1 Publications Verification DS-3201 tosylate	Histone Methyltransferase	Cancer
Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma .

HY-111149A

PS372424 hydrochloride 1 Publications Verification	CXCR	Inflammation/Immunology
PS372424 hydrochloride, a three amino-acid fragment of CXCL10, is a specific human CXCR3 agonist with anti-inflammatory activity. PS372424 hydrochloride prevents human T-cell migration in a humanized model of arthritic inflammation .

HY-N12687

Benzosceptrin C	PD-1/PD-L1 Apoptosis	Cancer
Benzosceptrin C is an inhibitor for PD-L1, which promotes programmed cell death ligand (PD-L1) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity .

HY-14171S

Bexarotene-d4 LGD1069 d₄	RAR/RXR Autophagy	Cancer
Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

HY-P99565

Tengonermin ARENEGYR; NGR-TNF; NGR-hTNF	TNF Receptor	Cancer
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .

HY-141432

NX-1607 Cbl-b-IN-3	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-3 (Compound 23) is a casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC₅₀ of < 1 nM. Cbl-b is an E3 ubiquitin ligase that negatively regulates T-cell activation .

HY-163194

Cbl-b-IN-16	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-16 (compound 31) is an orally active Cbl-b inhibtor with IC₅₀ of 30 nM and induces IL-2 production in Hu-T-cells with EC₅₀ of 230 nM. Cbl-b-IN-16 exhibits antitumor activity .

HY-N7038

Phytohemagglutinin 2 Publications Verification PHA-M	Others	Inflammation/Immunology
Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, Phaseolus vulgaris, accumulates in the parenchyma cells of the cotyledons. Phytohemagglutinin is a T-cell activator. Stimulation of human mononuclear leukocytes by Phytohemagglutinin induces the expression of ChAT mRNA, and potentiated ACh synthesis .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .

HY-155477

Cbl-b-IN-15	E1/E2/E3 Enzyme	Cancer
Cbl-b-IN-15 (compound 25) is an inhibitor of the RING finger E3 ligase Cbl (IC₅₀: 15 nM). Cbl-b refers to Casitas B-lineage lymphoma proto-oncogene-b, which inhibits T-cell, natural killer (NK) cell, and B-cell activation. Cbl-b-IN-15 activates T cell function with EC₅₀=0.41 μM .

HY-16984

GNE-4997
GNE-4997 is a potent and selective *interleukin-2-inducible T-cell* kinase (ITK) inhibitor with a K_i** of 0.09 nM, and the correlation between the basicity of solubilizing elements in GNE-4997 and off-target antiproliferative effects reduces cytotoxicity .

HY-120225

NJK14047	p38 MAPK	Inflammation/Immunology
NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice .

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

Cat. No.	Product Name	Type

HY-156087G

Cholicamideβ (GMP)	Fluorescent Dye
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

Cat. No.	Product Name	Type

HY-P1956

Human serum albumin

1 Publications Verification

HSA

Native Proteins

Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO ⁻) in the vascular wall, contributing to the reduction of blood pressure .

HY-151506

Phospholipid PL1	Drug Delivery
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity .

HY-156087G

Cholicamideβ (GMP)	Biochemical Assay Reagents
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis .

HY-W145657

Trehalose 6,6′-dimycolate

Cord Factor

Biochemical Assay Reagents

Trehalose 6,6'-dimycolate (Cord Factor) is trehalose 6,6'-dimycolate, a cell wall glycolipid of Mycobacterium tuberculosis, which can be used to simulate inflammation and granuloma induced by Mycobacterium tuberculosis (MTB) form. Trehalose 6,6′-dimycolate also protects Mycobacterium tuberculosis from macrophage-mediated killing, inhibits efficient antigen presentation, and reduces the development of protective T cell responses .

HY-153234

CD19 car circRNA-LNP

Drug Delivery

CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

HY-153233

CD19 car mRNA-LNP

Drug Delivery

CD19 car mRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

Cat. No.	Product Name	Target	Research Area

HY-P2455

LLO (91-99) Listeriolysin O (91-99)	Bacterial	Inflammation/Immunology
LLO (91-99) (Listeriolysin O (91-99)), an exotoxin, is a class I MHC-restricted T-cell epitopes of listeriolysin (LLO). LLO (91-99) is an essential antigen for induction of T-cell mediated immunity in vivo .

HY-P2511

Insulin β Chain Peptide (15-23)

Peptides Metabolic Disease

Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond .

HY-P2514

TET 830 modified/T-helper epitope from tetanus toxoid	Peptides	Inflammation/Immunology
TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope from tetanus toxoid. TET 830 modified/T-helper epitope from tetanus toxoid induces T-cells responses and is used as a helper peptide in vaccinations .

HY-P5425

Tetanus Toxin (830–844)	Peptides	Others
Tetanus Toxin (830–844) is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4+ T-cell epitope. This promiscuous CD4+ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4+ T-cell responses in a large part of the human population)

HY-P1996

Tiplimotide NBI-5788	Peptides	Neurological Disease Inflammation/Immunology
Tiplimotide (NBI-5788) is an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP). Tiplimotide can selectively reduce the production of inflammatory cytokines by pathogenic T-cells. Tiplimotide can be used for the research of multiple sclerosis (MS) .

HY-P1736

Influenza HA (126-138)	Influenza Virus	Infection
Influenza HA (126-138) is a influenza virus hemagglutinin (HA) peptide comprising amino acids 126-138, induces thymic and peripheral T-cell apoptosis .

HY-P3747

Hemagglutinin (48-68)	Influenza Virus	Infection
Hemagglutinin (48-68) is the 48-68 fragment of influenza virus hemagglutinin. Hemagglutinin (48-68) can induce proliferation of the peptide specific T-cell clones .

HY-P3644

EEKLIVVAF

Peptides Cancer

EEKLIVVAF is a pepitide, can be recognized on HLA-B44 by the anti-melanoma cytolytic T-cell (CTL) clone LB33- CTL-159/5 .

HY-P5496

AAV2 Epitope	Peptides	Others
AAV2 Epitope is a biological active peptide. (This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells.)

HY-P3719

MOG peptide (35-55)	Peptides	Inflammation/Immunology
MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4 ⁺ T cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model .

HY-P2561

Influenza Matrix Protein (61-72)	Influenza Virus	Infection Inflammation/Immunology
Influenza Matrix Protein (61-72) is a peptide fragment derived from matrix protein of influenza viruses, corresponds to amino acids 61-72. Influenza Matrix Protein (61-72) is a specific epitope which can induce CD4 ⁺ T-cell response .

HY-N7122A

Thymopentin acetate	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-P2560

LCMV GP (61-80)	Arenavirus	Infection Inflammation/Immunology
LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4 ⁺ T-cell response .

HY-P1914

NY-BR-1 p904 (A2)	Peptides	Cancer
NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1 .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P5499

CMV pp65(13-27)	Peptides	Others
CMV pp65(13-27) is a biological active peptide. (This peptide is derived from amino acid residues 13 to 27 of the 65k lower matrix phosphoprotein of the human cytomegalovirus. It contains a nine-amino-acid sequence (LGPISGHVL) that matches the consensus binding motif for a major histocompatibility complex H2-Dd T-cell epitope.)

HY-P2507

NY-ESO-1 (87-111)	Peptides	Cancer
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide sequence. NY-ESO-1 (87-111) binds to multiple HLA-DR and HLA-DP4 molecules, and stimulates Th1-type and Th-2/Th0-type CD4 ⁺ T cells when presented in the context of HLA-DR and HLA-DP4 molecules .

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function .

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P3444

CD31 PECAM-1	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation ^- .

HY-P3444A

CD31 TFA PECAM-1 TFA	SHP2 Bacterial	Metabolic Disease Inflammation/Immunology
CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM₆₈₆ and of SHP2 and to inhibit TCR-induced T-cell activation ^- .

HY-P5307

Peptide A5K INF7-A5K-TAT	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) is an RNP delivery peptide that delivers CRISPR RNPs to T cells. Peptide A5K effectively edits T cells without substantial impact on T cell viability .

HY-P3723

MBP (83-99)	Peptides	Inflammation/Immunology
MBP (83-99) is a MBP-specific T cell lines recognizing the immunodominant epitope. MBP (83-99) induces proliferation and IFN-γ secreting of T cells .

HY-W019721

Cyclosporin D	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A . Cyclosporin A is a potent immunosuppressant agent, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc) .

HY-P0287

QL9

Peptides Inflammation/Immunology

QL9 (QLSPFPFDL) is a high-affinity alloantigen for the 2C T cell receptor (TCR).

HY-P1822

BDC2.5 mimotope 1040-31	Peptides	Metabolic Disease
BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg ⁺T cells .

HY-P1822A

BDC2.5 mimotope 1040-31 TFA	Peptides	Metabolic Disease
BDC2.5 mimotope 1040-31 TFA, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg ⁺T cells .

HY-P3638

Binetrakin	Peptides	Inflammation/Immunology
Binetrakin (Interleukin 4 (human)) is a T lymphocyte-derived pleiotrophic cytokine that affects a variety of cell types including B cells and T cells. Binetrakin induces differentiation of naive helper T cells (Th0 cells) to Th2 cells. Binetrakin can be used for the research of many biological .

HY-P0287A

QL9 TFA

Peptides Inflammation/Immunology

QL9 (QLSPFPFDL) TFA is a high-affinity alloantigen for the 2C T cell receptor (TCR).

HY-P5488

BDC2.5 Mimotope 1040-63	Peptides	Others
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)

HY-P2525

GAD65 (206-220)	Peptides	Inflammation/Immunology
GAD65 (206-220) is glutamic acid decarboxylase (GAD) 65-derived peptide, corresponding to residues 180-188. GAD65 is presented to T cells in association with I-Ag7 MHC class II molecules and a major pancreatic antigens targeted by self-reactive T cells in type I diabetes mellitus .

HY-P5396

GAD65 (524-543)	Peptides	Others
GAD65 (524-543) is a biological active peptide. (This is amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). It is one of the first fragments of this islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. This peptide is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with p524–543 increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells.)

HY-P1089

Cytochrome c-pigeon (88-104) PCC 88-104	Peptides	Inflammation/Immunology
Cytochrome c-pigeon (88-104) (PCC 88-104) has full stimulatory activity for pigeon cytochrome c-primed T cells from B10.A mice. The I-E ^k-restricted T cell response to Cytochrome c pigeon (pcyt c) is specific for the COOH-terminal sequence 88-104 .

HY-P4628

TPNQRQNVC

LRH-1 peptide
Peptides Inflammation/Immunology

TPNQRQNVC is a nonapeptide and is the epitope of HLA-B0702. TPNQRQNVC induces a CD8+ T cell immune response .
HY-P0260

p2Ca

Peptides Inflammation/Immunology

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.
HY-P5442

MOG (44-54), mouse, human, rat

Peptides Others

MOG (44-54), mouse, human, rat is a biological active peptide. (minimal binding epitope for the CD8 + MOG‐specific T cell)

HY-P5502

Influenza NP (311-325)	Peptides	Others
Influenza NP (311-325) is a biological active peptide. (This peptide is amino acids 311 to 325 fragment of the influenza virus nucleoprotein (NP). This bona fide MHC class II restricted epitope from influenza virus was used to study the host immunoresponse during the infection. This peptide elicits the strongest gamma interferon (IFN-gamma) production in the intracellular cytokine assays. It does not stimulate CD8 T-cells in mice.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P1026

NFAT Inhibitor-1 Maximum Cited Publications 11 Publications Verification VIVIT peptide	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
NFAT Inhibitor (VIVIT peptide) is a cell-permeable peptide inhibitor of *nuclear factor of activated Tcells* (NFAT) that selectively inhibits calcineurin-mediated dephosphorylation of NFAT** .

HY-P1811

Iα52	Peptides	Inflammation/Immunology
Iα52 is a naturally processed peptide encompassed the residues 52-68 of the murine I-Eα chain and may contribute to selection of immature T cells .

HY-P5870

KTX-Sp2	Potassium Channel	Inflammation/Immunology
KTX-Sp2 is a potassium channel toxin. KTX-Sp2 effectively blocks three types of exogenous voltage-gated potassium channels: Kv1.1, Kv1.2 and Kv1.3. Ktx-Sp2 inhibits endogenous Kv1.3 and suppresses Ca ²⁺ signaling in Jurkat T cells. Ktx-Sp2 inhibits IL-2 secretion from activated Jurkat T cells .

HY-P1430

11R-VIVIT Cell permeable NFAT inhibitor	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT can be used for the research of podocyte and diabetic nephropathy .

HY-P1910

BDC2.5 mimotope 1040-51

Peptides Metabolic Disease

BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice .

HY-P1430A

11R-VIVIT TFA 5+ Cited Publications Cell permeable NFAT inhibitor TFA	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy .

HY-P5745

TYVPANASL

Peptides Cancer

TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

HY-P5745A

TYVPANASL TFA

Peptides Cancer

TYVPANASL TFA is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL TFA can be used to prepare J-LEAPS vaccine .

HY-P1771

OVA G4 peptide	Peptides	Inflammation/Immunology
OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P1771A

OVA G4 peptide TFA	Peptides	Inflammation/Immunology
OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel .

HY-P5294

YLLEMLWRL	Peptides	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

Cat. No.	Product Name

HY-K0304

*Human CD3+ T Cells* Negative Selection Kit**
MCE Human CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from human peripheral blood mononuclear cells (PBMC).

HY-K0306

*Mouse CD3+ T Cells* Negative Selection Kit**
MCE Mouse CD3⁺ T Cells Negative Selection Kit is designed for the isolation of CD3⁺ T cells from single cell suspensions of mouse spleen cells, lymph nodes or other tissues.

HY-K0307

*Mouse CD4+ T Cells* Negative Selection Kit**
MCE Mouse CD4⁺ T Cells Negative Selection Kit is designed for the isolation of CD4⁺ T cells from single cell suspensions of mouse spleen cells, lymph nodes or other tissues.

HY-K0309

*Mouse CD8+ T Cells* Negative Selection Kit**
MCE Mouse CD8⁺ T Cells Negative Selection Kit is designed for the isolation of CD8⁺ T cells from single cell suspensions of mouse spleen cells, lymph nodes or other tissues.

HY-K0308

*Mouse CD4+ Cell* Positive Selection Kit**
MCE Mouse CD4⁺ T Cells Positive Selection Kit is designed for the isolation of CD4⁺ cells from single cell suspensions of mouse spleen cells, lymph nodes or other tissues.

Cat. No.	Product Name	Target	Research Area

HY-P99051

Tinurilimab BAY 1834942	Inhibitory Antibodies	Inflammation/Immunology Cancer
Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors .

HY-P99798

Pacanalotamab AMG 420; BI-836909	CD3	Cancer
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3ɛ. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .

HY-P99378

Neihulizumab ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)	Apoptosis	Inflammation/Immunology
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .

HY-P99266

Zanolimumab Anti-Human CD4 Recombinant Antibody	Inhibitory Antibodies	Inflammation/Immunology Cancer
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .

HY-P99726

Maslimomab

Inhibitory Antibodies Inflammation/Immunology

Maslimomab is a murine monoclonal antibody targeting T-cell receptor. Maslimomab is an immunosuppressive agent .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells* to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P99679

Izuralimab

PD-1/PD-L1 Inflammation/Immunology Cancer

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1 .

HY-P99430

Alnuctamab EM901; CC-93269	Inhibitory Antibodies	Inflammation/Immunology
Alnuctamab (EM901) is an asymmetric 2-arm, humanized IgG T-cell engager (TCE). Alnuctamab can be used for immune research .

HY-P99508

Tamgiblimab IBI939	Inhibitory Antibodies	Cancer
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects .

HY-P99931

Epcoritamab GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-P99024

Glofitamab RO7082859	CD20	Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma .

HY-P99040

Onvatilimab JNJ-61610588	PD-1/PD-L1	Cancer
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-*VISTA (V-domain Ig Suppressor of T-cell* Activation)** monoclonal antibody. Onvatilimab has an anti-tumor activity .

HY-P99717

Lulizumab pegol BMS-931699	CD28	Inflammation/Immunology
Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist. Lulizumab pegol effectively inhibits T-cell proliferation and it can be used for the reseach of kidney transplantation and autoimmunity disease .

HY-P99565

Tengonermin ARENEGYR; NGR-TNF; NGR-hTNF	TNF Receptor	Cancer
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .

HY-P99369

Lacutamab IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)	Inhibitory Antibodies	Cancer
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .

HY-P99579

Tamtuvetmab AT-005; AT005	Inhibitory Antibodies	Cancer
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Inflammation/Immunology Cancer
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 ⁺ non-Hodgkin lymphomas (NHL) .

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99922

Encelimab	Inhibitory Antibodies	Cancer
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .

HY-108829

Abatacept CTLA4lg; BMS-188667	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-P9986

Tiragolumab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC) .

HY-P99933

Eftilagimod alfa IMP321; LAG-3Ig	LAG-3	Cancer
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

HY-P990104

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99203

Cemiplimab	PD-1/PD-L1	Cancer
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .

HY-108829A

Abatacept (powder) CTLA4lg (powder); BMS-188667 (powder)	CTLA-4	Inflammation/Immunology Cancer
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .

HY-P99962

Surzebiclimab BGB-A425	Mucin	Cancer
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (K_D=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .

HY-P99419

Acasunlimab GEN1046	PD-1/PD-L1	Cancer
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .

HY-P99055

Urelumab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99252

Itolizumab Anti-Human CD6 Recombinant Antibody	CD6	Infection Inflammation/Immunology
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .

HY-P99904

Siplizumab MEDI-507	CD2	Inflammation/Immunology
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .

HY-P9947

Efalizumab	Integrin	Others
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .

HY-P99392

Teclistamab	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99431

KY-1044 Alomfilimab; SAR 445256	Inhibitory Antibodies	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99575

Tarlatamab AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P99033

Mosunetuzumab BTCT-4465A	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .

HY-P99790

Priliximab CEN 000029; cM-T412	Inhibitory Antibodies	Inflammation/Immunology
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 ⁺ T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .

HY-P99573

Tebotelimab MGD-013	LAG-3	Inflammation/Immunology Cancer
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4053

Heraclenin	Structural Classification Classification of Application Fields Source classification Coumarins Phenylpropanoids Plants Umbelliferae Seriphidium transiliense Inflammation/Immunology Disease Research Fields	Nuclear Factor of activated T Cells (NFAT)
Heraclenin, a natural furanocoumarin, significantly inhibits T cell receptor-mediated proliferation in human primary T cells in a concentration-dependent manner by targeting nuclear factor of activated T-cells (NFAT) .

HY-N7038

Phytohemagglutinin 2 Publications Verification PHA-M	Natural Products Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Plants Disease Research Fields Inflammation/Immunology	Others
Phytohemagglutinin (PHA-M), the major seed lectin of the common bean, Phaseolus vulgaris, accumulates in the parenchyma cells of the cotyledons. Phytohemagglutinin is a T-cell activator. Stimulation of human mononuclear leukocytes by Phytohemagglutinin induces the expression of ChAT mRNA, and potentiated ACh synthesis .

HY-N7122A

Thymopentin acetate	Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Inflammation/Immunology	Endogenous Metabolite
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-N12687

Benzosceptrin C	Structural Classification Alkaloids Pyrrole Alkaloids Marine natural products Source classification	PD-1/PD-L1 Apoptosis
Benzosceptrin C is an inhibitor for PD-L1, which promotes programmed cell death ligand (PD-L1) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity .

HY-N12613

Sydowimide A	Structural Classification Natural Products Microorganisms Marine natural products Source classification Marine microorganism	Phosphatase
Sydowimide A is a potent inhibitor of Src homology region 2 domain-containing phosphatase-1 (SHP1), T-cell protein tyrosine phosphatase (TCPTP) and leukocyte common antigen (CD45), with IC₅₀ values of 1.5, 2.4 and 18.83 μM, respectively .

HY-N7119

Cimicifugoside	Triterpenes Classification of Application Fields Terpenoids Source classification Ranunculaceae Plants Cimicifuga foetida Linn. Disease Research Fields Inflammation/Immunology	Others
Cimicifugoside, a triterpenoid isolated from Cimicifuga simplex, is a novel specific nucleoside transport inhibitor that displays synergistic potentiation of methotrexate cytotoxicity . Cimicifugoside shows immunosuppressive activity, which is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function .

HY-N10649

PTP1B-IN-21	Quinones Anthraquinones Rubiaceae Knoxia valerianoides Thorel ex Pitard Plants	Phosphatase
PTP1B-IN-21 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC₅₀=1.56 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC₅₀>100 μM), which is a key target for type 2 diabetes inhibition .

HY-N10648

PTP1B-IN-20	Quinones Anthraquinones Rubiaceae Knoxia valerianoides Thorel ex Pitard Plants	Phosphatase
PTP1B-IN-20 is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B; IC₅₀=1.05 μM) over the highly homologous T-cell protein tyrosine phosphatase (TCPTP; IC₅₀=78.0 μM), which is a key target for type 2 diabetes inhibition .

HY-19356

Rocaglamide Maximum Cited Publications 20 Publications Verification Roc-A; MG-002	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Source classification Plants Meliaceae Disease Research Fields Aglaia elliptifolia Cancer	NF-κB HSP Eukaryotic Initiation Factor (eIF)
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia .

HY-N3037

3-O-Acetyl-α-boswellic acid α-Boswellic acid acetate	Other Terpenoids Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	Others
3-O-Acetyl-α-boswellic acid suppresses T cell function .

HY-W019721

Cyclosporin D	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields	Nuclear Factor of activated T Cells (NFAT)
Cyclosporin D, a metabolite of Cyclosporin A, is a weak immunosuppressant. Cyclosporin D is used as internal standard for quantification of Cyclosporin A . Cyclosporin A is a potent immunosuppressant agent, suppress T cell activation by inhibiting calcineurin and the calcineurin-dependent transcription factors nuclear factor of activated T cells (NFAc) .

HY-119527

Conagenin	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Others
Conagenin is an immunomodulator. Conagenin shows antitumor effects by activation of T cells and increasing antitumor effector cells .

HY-119347

Cirsilineol 1 Publications Verification	Laburnum anagyroides Medic. Flavonoids Monophenols Classification of Application Fields Flavones Source classification Phenols Plants Compositae Disease Research Fields Inflammation/Immunology	IFNAR STAT
Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4 ⁺ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice .

HY-N9737

(−)-Acutumine	Structural Classification Alkaloids Pyrrole Alkaloids Source classification Plants Menispermaceae	Others
(−)-Acutumine is a tetracyclic chloroalkaloid that exhibits selective cytotoxicity to cultured human T cells and memory-enhancing properties in the Wistar rat model .

HY-P0260

p2Ca	Natural Products Classification of Application Fields Animals Source classification Disease Research Fields Inflammation/Immunology	Others
p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

HY-104026B

L-Kynurenine sulfate	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite Aryl Hydrocarbon Receptor
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-145491

Resolvin D5	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	ERK NF-κB
Resolvin D5 is a prolytic mediator (SPM) with anti-inflammatory activity derived from oxidized lipids DHA. Resolvin D5 inhibits Th17 cell differentiation and promotes regulatory T cell differentiation, and inhibits CD4+ T cell proliferation. Resolvin D5 attenuates osteoclast differentiation and interferes with osteoclastogenesis. Resolvin D5 also regulates ERK phosphorylation and nuclear translocation of NF-kappaB. Resolvin D5 could be used in rheumatoid arthritis research .

HY-N6681

15-Acetoxyscirpenol	Infection Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Disease Research Fields	Caspase Bacterial Apoptosis Antibiotic
15-acetoxyscirpenol, one of acetoxyscirpenol moiety mycotoxins (ASMs), strongly induces apoptosis and inhibits Jurkat T cell growth in a dose-dependent manner by activating other caspases independent of caspase-3 .

HY-N4171

Dihydrocucurbitacin B	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields	Apoptosis
Dihydrocucurbitacin B, a triterpene isolated from Cayaponia tayuya roots, inhibits nuclear factor of activated T cells (NFAT), induces cell cycle arrested in the G0 phase, and inhibits delayed type hypersensitivity .

HY-N7087

Tulipalin A α-Methylene butyrolactone	Liliaceae Ketones, Aldehydes, Acids Source classification Tulipa gesneriana L. Plants	Drug Metabolite
Tulipalin A (α-Methylene butyrolactone) is a glycoside. Tulipalin A is a causative allergen that induces Allergic contact dermatitides . Tulipalin A (α-Methylene butyrolactone) at low dose affects the functionality of immune cells, such as Jurkat T cells .

HY-113042

Prostaglandin B2	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite
Prostaglandin B2 is a prostaglandin. Prostaglandin B2 is the main substance in cord blood mesenchymal stem cells, to inhibit DC-T Cell proliferation. Prostaglandin B2 also induces cutaneous vasoconstriction of the canine hind paw .

HY-114495

Caerulomycin A 1 Publications Verification Cerulomycin; Caerulomycin	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Anticancer Inflammation/Immunology Disease Research Fields Other Antibiotics	Fungal Antibiotic
Caerulomycin A (Cerulomycin; Caerulomycin), an antifungal compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases .

HY-N7819

Pristane Norphytane	Structural Classification other families Classification of Application Fields Terpenoids Source classification Marine natural products Other marine organisms Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Others
Pristane (Norphytane) is a naturally occurring hydrocarbon oil found in small quantities in many plants, in various marine organisms, and as the most active component of mineral oil . Pristane is a non-antigenic adjuvant, and induces MHC class II-restricted, arthritogenic T cells in the rat .

HY-N3796

Echinulin Echinuline	Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Inflammation/Immunology Indole Alkaloids	NF-κB
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to NF-κB activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent .

HY-101775A

9-Hydroxyellipticine hydrochloride	Structural Classification Alkaloids Carbazole Alkaloids	Topoisomerase
9-Hydroxyellipticine hydrochloride is a inhibitor of Topo II and RyR. 9-Hydroxyellipticine hydrochloride exhibits antitumor, antioxidant and catecholamine-releasing activities. 9-Hydroxyellipticine hydrochloride exhibits IC₅₀ values of 1.6 μM and 1.2μM in Hela S-3 and 293T cells, respectively .

HY-N0041

Ginsenoside Rb3 Gypenoside IV	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae Cancer	NF-κB COX NO Synthase
Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.

HY-N9965

2'-Fucosyllactose 2'-FL	Infection Structural Classification Polysaccharides Classification of Application Fields Animals Inflammation/Immunology Disease Research Fields Saccharides	TNF Receptor Interleukin Related
2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines .

HY-N12537

PD-1/PD-L1-IN-38	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	PD-1/PD-L1
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .

HY-N0041R

Ginsenoside Rb3 (Standard) Gypenoside IV (Standard)	Panax ginseng C. A. Meyer Structural Classification Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae Cancer	NF-κB COX NO Synthase
Ginsenoside Rb3 (Standard) is the analytical standard of Ginsenoside Rb3. This product is intended for research and analytical applications. Ginsenoside Rb3 is extracted from steamed Panax ginseng C. A. Meyer. Ginsenoside Rb3 exhibits inhibitory effect on TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 8.2 μM in 293T cell lines. Ginsenoside Rb3 also inhibits the induction of COX-2 and iNOS mRNA.

HY-113962

7α,25-Dihydroxycholesterol 1 Publications Verification 7α,25-OHC	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids	EBI2/GPR183 Endogenous Metabolite
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC₅₀=140 pM; K_d=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells .

HY-N10295

Flavipin	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Inflammation/Immunology	Aryl Hydrocarbon Receptor
Flavipin is an aryl hydrocarbon receptor (Ahr) agonist that induces the expression of Ahr downstream genes in mouse CD4 ⁺ T cells and CD11b ⁺ macrophages. Flavipin inhibits the stabilizing function of Arid5a on Il23a 3′UTR, a newly identified target mRNA . Flavipin exhibits the DPPH free radical scavenging ability with IC₅₀ value of 7.2 μM, and has potent α-glucosidase inhibition with IC₅₀ value of 33.8 μM .

HY-N12422

A2AAR antagonist 2	Structural Classification Natural Products Liliaceae Source classification Allium cepa L. Plants	Adenosine Receptor
3′-Methoxyfurano[4″,5″:3,4]chalcone (compound 2) is a selective A_2AAR antagonist (IC₅₀=33.5 nM) with high affinity. 3′-Methoxyfurano[4″,5″:3,4]chalcone is also a natural product obtained from the bark of Allium cepa L. 3′-Methoxyfurano[4″,5″:3,4]chalcone can promote T cell activation and can be used in cancer immunity research .

HY-N12537A

(2R,3S)-PD-1/PD-L1-IN-38	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	Aryl Hydrocarbon Receptor PD-1/PD-L1
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 .

HY-116330

Hyperforin	Structural Classification Anti-inflammation/Immunoregulatory Antibiotics Source classification Guttiferae Hyperlcurn perforatum L. Disease Research Plants Anticancer	Calcium Channel TRP Channel
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-116330A

Hyperforin dicyclohexylammonium salt 1 Publications Verification Hyperforin DCHA	Structural Classification Natural Products Source classification Guttiferae Hyperlcurn perforatum L. Plants	TRP Channel Calcium Channel
Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

Species:	Human (2)
Tag:	His (2) B2M (1)
Source:	HEK293 (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71544

	MLANA Protein, Human (His, B2M) Antigen LB39 AA; Antigen LB39-AA; Antigen SK29 AA; Antigen SK29-AA; MAR1_HUMAN; MART 1; MART-1; MART1; Melan A; Melan A protein; Melanoma antigen recognized by T cells 1; Melanoma antigen recognized by T-cells 1; MLAN A; MLANA; OTTHUMP00000021036; OTTHUMP00000021037; OTTHUMP00000021038; Protein Melan-A	Human	E. coli
	The MLANA protein is essential in melanosome biosynthesis, ensuring the stability of GPR143, and plays a key role in the expression, stability, transport, and processing of the melanocyte protein PMEL. Its interaction with PMEL and GPR143 highlights its integral role in the complex network required for second-stage melanosome formation. MLANA Protein, Human (His, B2M) is the recombinant human-derived MLANA protein, expressed by E. coli , with N-His, B2M labeled tag. The total length of MLANA Protein, Human (His, B2M) is 118 a.a., with molecular weight of ~27.2 kDa.

HY-P71173

	NTAL Protein, Human (HEK293, His) Linker for Activation of T-cells Family Member 2; Linker for Activation of B-cells; Membrane-Associated Adapter Molecule; Non-T-Cell Activation Linker; Williams-Beuren Syndrome Chromosomal Region 15 Protein; Williams-Beuren Syndrome Chromosomal Region 5 Protei	Human	HEK293
	NTAL protein is critical for FCER1 downstream signaling in mast cells and is involved in BCR-mediated signaling in B cells and FCGR1-mediated signaling in myeloid cells. It acts as a molecular bridge, recruiting GRB2 upon phosphorylation, linking receptor activation to intracellular responses. NTAL Protein, Human (HEK293, His) is the recombinant human-derived NTAL protein, expressed by HEK293 , with C-6*His labeled tag. The total length of NTAL Protein, Human (HEK293, His) is 217 a.a., with molecular weight of 35-40 kDa.

Cat. No.	Product Name	Chemical Structure

HY-14171S

Bexarotene-d4
Bexarotene-d₄ is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma[1][2][3][4][5].

HY-B0172AS

Isoallolithocholic acid-d2
Isoallolithocholic acid-d₂ is the deuterium labeled Isoallolithocholic acid (HY-B0172A). Isoallolithocholic acid is a T cell regulator and enhances regulatory T cells (Tregs) differentiation[1][2].

HY-104026CS

L-Kynurenine-13C10 sulfate hemihydrate
L-Kynurenine- ¹³C10 (sulfate hemihydrate) is the ¹³C labeled L-Kynurenine sulfate. L-Kynurenine sulfate hemihydrate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-149773S

HPK1-IN-40-d2
HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC₅₀ of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity .

HY-104026BS

L-Kynurenine-13C10 sulfate
L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-B0190S1

Nafamostat formate salt-13C6
Nafamostat formate salt- ¹³C₆ is the ¹³C labeled Nafamostat[1]. Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2[2][3][4][5].

HY-N7819S

Pristane-d40
Pristane-d₄₀ is the deuterium labeled Pristane[1]. Pristane (Norphytane) is a naturally occurring hydrocarbon oil found in small quantities in many plants, in various marine organisms, and as the most active component of mineral oil[2]. Pristane is a non-antigenic adjuvant, and induces MHC class II-restricted, arthritogenic T cells in the rat[3].

HY-117433S

4-Hydroperoxy Cyclophosphamide-d4

4-Hydroperoxy Cyclophosphamide-d₄ is the deuterium labeled 4-Hydroperoxy cyclophosphamide. 4-Hydroperoxy cyclophosphamide is the active metabolite form of the proagent Cyclophosphamide. 4-Hydroperoxy cyclophosphamide crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS). 4-Hydroperoxy cyclophosphamide has the potential for lymphomas and autoimmune disorders[1][2].

HY-A0003S

Lenalidomide-d5

Lenalidomide-d₅ is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

Cat. No.	Product Name	Application	Reactivity

HY-P83295

MelanA Antibody (YA3040)

MLANA; MART1; Melanoma antigen recognized by T-cells 1; MART-1; Antigen LB39-AA; Antigen SK29-AA; Protein Melan-A
WB, IHC-P, ICC/IF, FC Human
HY-P83416

LAT Antibody (YA3161)

LAT; Linker for activation of T-cells family member 1; 36 kDa phospho-tyrosine adapter protein; pp36; p36-38
WB, IHC-P, IP Human
HY-P81297

Phospho-LAT (Tyr191) Antibody (YA1021)

LAT; Linker for activation of T-cells family member 1; 36 kDa phospho-tyrosine adapter protein; pp36; p36-38
WB, IHC-P, ICC/IF, IP Human, Mouse, Rat
HY-P81297A

Phospho-LAT (Tyr200) Antibody (YA1022)

LAT; Linker for activation of T-cells family member 1; 36 kDa phospho-tyrosine adapter protein; pp36; p36-38
WB Human

HY-P81644

Phospho-NFAT2 (Ser237) Antibody (YA1389) NFATC1; NFAT2; NFATC; Nuclear factor of activated T-cells; cytoplasmic 1; NF-ATc1; NFATc1; NFAT transcription complex cytosolic component; NF-ATc; NFATc	WB	Human, Mouse

HY-P82159

ILF3 Antibody (YA1904) ILF3; DRBF; MPHOSPH4; NF90; Interleukin enhancer-binding factor 3; Double-stranded RNA-binding protein 76; DRBP76; M-phase phosphoprotein 4; MPP4; Nuclear factor associated with dsRNA; NFAR; Nuclear factor of activated T-cells 90 kDa; NF-AT-90; Translational control protein 80; TCP80	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse

Cat. No.	Product Name		Classification

HY-10446

Pralatrexate 4 Publications Verification		Alkynes
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a K_i of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment . Pralatrexate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

T-cells

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products